A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer (NCT05563766)
🩺 Plain-English Summary (8th-Grade Level)
Esophageal cancer, which has a low 5-year overall survival rate (\<20%) is increasing in incidence. Previous studies have shown that Hedgehog, AKT, and angiogenic signaling pathways are activated in a significant number of esophageal cancers. Itraconazole, a widely used anti-fungal medication, effectively inhibits these pathways. In this multi-site phase II trial, the investigators will evaluate the effect of itraconazole as a neoadjuvant therapy added to standard of care chemoradiation and surgery in the the treatment of locoregional esophageal and gastroesophageal junction cancers.
Who can join: Review the eligibility criteria below.
Location: VA Palo Alto Health Care System, Palo Alto, CA — Palo Alto, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (7 Sites)
- VA Palo Alto Health Care System, Palo Alto, CA — Palo Alto, California
- VA Ann Arbor Healthcare System, Ann Arbor, MI — Ann Arbor, Michigan
- Durham VA Medical Center, Durham, NC — Durham, North Carolina
- VA Portland Health Care System, Portland, OR — Portland, Oregon
- VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX — Dallas, Texas
- Michael E. DeBakey VA Medical Center, Houston, TX — Houston, Texas
- VA Puget Sound Health Care System Seattle Division, Seattle, WA — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (650) 493-5000
Email: albert.lin6@va.gov
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Esophageal Adenocarcinoma
- Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer — Basking Ridge, New Jersey
- Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction — New York, New York
- Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma — Los Angeles, California
- Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma — Durham, North Carolina
- Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma — Madison, Wisconsin
Explore by condition: All Esophageal Adenocarcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.